ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ARTBIO-3B-Pharma

More Like This

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

PR Newswire associated0

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

PR Newswire associated0

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

PR Newswire associated0

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors